Using muscle assessment to predict health outcomes in liver disease patients
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
This study is testing if a quick muscle check during an MRI can help predict health outcomes for patients with liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05264051 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the Muscle Assessment Score (MAsS) using MRI as an objective measure of frailty and muscle composition in patients with liver disease. It will involve a prospective analysis of patients already scheduled for MRI at the University of Chicago Medical Center, focusing on four specific groups: those hospitalized with acute hepatic decompensation, patients with hepatobiliary neoplasia, individuals undergoing TIPS placement, and those with chronic liver disease. The MAsS assessment will add an additional 8-10 minutes to the MRI procedure, allowing researchers to gather valuable data on the correlation between muscle composition and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with liver disease who are already scheduled for an MRI for routine clinical purposes.
Not a fit: Patients under 18 years of age will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this study could provide a new predictive tool for assessing morbidity and mortality risks in liver disease patients.
How similar studies have performed: While the use of muscle assessment in liver disease is a growing area of interest, this specific approach utilizing MAsS and MRI is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated Exclusion Criteria: * \<18 yrs. of age
Where this trial is running
Chicago, Illinois
- The University of Chicago — Chicago, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Omar Jamil, MD
- Email: Omar.Jamil@uchospitals.edu
- Phone: 847-373-2360
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.